Last week OBIO hosted Gary Svoboda (CEO, Adventus Research + Consulting) who provided the audience practical steps they can use to validate technology with primary market research.
This year's AdvaMed MedTech Conference in Boston was a fantastic event. OBIO was in attendance for meetings and conversations with US and global investors and strategics about what's coming up for the health science industry in Canada. There was tons of enthusiasm and interest to capitalize on as we head into 2020.
On September 17th, OBIO held a dinner to bring together CAAP and CAAP Alumni companies. OBIO would like to thank everyone who came out and joined us to discuss common experiences, challenges and what's coming next.
On September 10th, OBIO organized a cross-border networking event in Boston at the Consulate General of Canada. The event was supported by the Consulate General and law firms Fasken and Choate. Over 45 investors, strategics, as well as executives from high potential Canadian health science companies packed the Canada Room at the Consulate and resulted in numerous investor-company interactions.
FedDev Ontario is investing up to $6.24 million for the Ontario Bioscience Innovation Organization (OBIO®) to boost investment, market access and mentorship opportunities for companies across southern Ontario looking to commercialize their medical innovations.
On August 21st, OBIO hosted Norton Rose Fulbright’s Anthony de Fazekas (Partner, Head of Technology & Innovation) and Vanessa Grant (Partner), Lumira Ventures’ Jacki Jenuth (Partner), and University of Toronto’s Karen Temple (Commercialization Manager) who discussed practical considerations for licensing health science technologies from tech transfer offices, and how these agreements can impact a company’s future investability.
On July 25th, OBIO hosted a Happy Hour Networking event attended by over 40 CEOs and senior health science company executives. Attendees networked with fellow entrepreneurs and heard about OBIO’s upcoming plans for the fall.
The OBIO 2020 Niagara Investment Summit national call for applications from health science companies that are seeking Series A or beyond investments is now open.
On July 11th, OBIO presented the “Optimize your next round of funding” workshop for CAAP & Health MINT companies. The workshop was led by Nick Kuryluk of Virtus Insights.
On June 25th, OBIO hosted 'Is the Price Right? Pricing Your Innovative Healthcare Product' which featured a presentation by Amy Siegel (C-Founder, S2N Health).
If your company has experience with an unnecessary, duplicative or frustrating hurdle in the course of doing business, OBIO wants to know. Please tell us what the challenges are and how they impact your company. As part of OBIO’s engagement with the provincial government, the health science industry’s recommendations on red tape or regulatory burdens that can be addressed are being sought by the Government of Ontario.
On June 10th, OBIO hosted a Pitches & Pitchers event, supported by Lumira Ventures and Whitecap Venture Partners.
In the latest issue of Biotechnology Focus, OBIO President and CEO Gail Garland contributed a special report: Why Ontario needs a network of Early Adopter Health Organizations
On May 13th, OBIO hosted the 2019 Queen’s Park Health Science Industry Showcase which attracted over 100 attendees, including Ministers, MPPs, government officials and health science industry leaders who came to see the latest in health care innovation from our displaying companies.
Apply to be one of 4 OBIO member companies to pitch to the Mid Atlantic Bio Angels (MABA), a group of active angel investors based in New York City. Companies will receive constructive feedback on what they need to have in place prior to applying for investment from MABA or similar groups to improve their chances of getting investment.
The Ontario Bioscience Innovation Organization (OBIO®) today released its latest report, ‘Achieving Impact Through Adoption of Innovative Health Technologies: Establishing Early Adopter Health Organizations as an Accelerator for Economic Growth in Ontario’, which describes an early adopter model to facilitate the evaluation and adoption of innovative health technologies in Ontario health organizations.
The Ontario Bioscience Innovation Organization (OBIO®) is proud to announce its 2019 Capital Access Advisory Program (CAAP®) and the high-potential health science companies in this year’s program.
Last week, the 2019 Federal Budget was introduced and it included some announcements and changes that health science companies should be aware of.
OBIO® (Ontario Bioscience Innovation Organization) is proud to announce the success of the 2019 Niagara Investment Summit on February 20-22, 2019. The 2019 Niagara Investment Summit featured over 30 of Canada’s most promising innovative health science companies and more than 30 US and global investors and VCs.